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Abstract: Deficiencies in mismatch repair (MMR) are associated with carcinogenesis. Rhodium metalloin-
sertors bind to DNA base mismatches with high specificity and inhibit cellular proliferation preferentially in
MMR-deficient cells versus MMR-proficient cells. A family of chrysenequinone diimine complexes of rhodium
with varying ancillary ligands that serve as DNA metalloinsertors has been synthesized, and both DNA
mismatch binding affinities and antiproliferative activities against the human colorectal carcinoma cell lines
HCT116N and HCT116O, an isogenic model system for MMR deficiency, have been determined. DNA
photocleavage experiments reveal that all complexes bind to the mismatch sites with high specificities;
DNA binding affinities to oligonucleotides containing single base CA and CC mismatches, obtained through
photocleavage titration or competition, vary from 104 to 108 M-1 for the series of complexes. Significantly,
binding affinities are found to be inversely related to ancillary ligand size and directly related to differential
inhibition of the HCT116 cell lines. The observed trend in binding affinity is consistent with the metalloinsertion
mode where the complex binds from the minor groove with ejection of mismatched base pairs. The
correlation between binding affinity and targeting of the MMR-deficient cell line suggests that rhodium
metalloinsertors exert their selective biological effects on MMR-deficient cells through mismatch binding in
vivo.
Introduction
The mismatch repair (MMR) pathway corrects single base
errors and insertion/deletion loops that arise during DNA
synthesis, increasing the fidelity of DNA replication by a factor
of 50-1000.1 If uncorrected, mismatches are converted to
mutations in subsequent cycles of DNA replication, and cells
with MMR deficiencies, not surprisingly, exhibit elevated
mutation rates.2-4 Germline mutations in hMLH1 or hMSH2,
essential genes for MMR in humans, dramatically increase the
risk of developing hereditary nonpolyposis colon cancer
(HNPCC), the most common type of inherited colon cancer.5,6
HNPCC is marked by early onset and the presence of cancers
in several other tissue types.6 Roughly 15% of sporadic
colorectal cancer cases have also been linked to MMR defi-
ciency.7 Epigenetic silencing of the MMR genes has been
identified as the cause of MMR deficiency in these cases.8 In
addition to colorectal cancer, mismatch repair deficiencies have
been found in approximately 16% of solid tumors of all tissue
types.3,9
Importantly, MMR deficiency confers resistance or tolerance
to many of the anti-cancer agents currently in clinical use.10,11
Alkylation by the commonly used chemotherapeutic agents
N-methyl-N-nitrosourea (MNU) and N-methyl-N′-nitro-N-ni-
trosoguanidine (MNNG) at the O6 position of guanine nucle-
otides triggers an apoptotic response after recognition of O6-
meG:C and O6-meG:T base pairs by the MMR pathway, while
MMR-deficient cells tolerate this DNA methylation.10-12 Failure
to recognize DNA adducts is also involved in the resistance of
MMR-deficient cells to the platinum compounds cisplatin and
carboplatin.10-13 The incorporation of anti-metabolites such as
5-fluorouracil and 6-thioguanine into DNA triggers cell cycle
arrest and apoptosis through the MMR pathway, and conse-
quently MMR-deficient cells are resistant to these agents as
well.14,15 Other studies have shown low-level resistance to the
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type I topoisomerase poisons camptothecin and topotecan in
hMLH1 deficient lines and to the type II topoisomerase poisons
doxorubicin, epirubicin, and mitoxantrone in hMLH1 or hMSH2
deficient lines.16 It has also been hypothesized that treatment
regimens with agents such as cisplatin might enrich tumors for
MMR-deficient cells,17 and it has been shown that a substantial
portion of secondary, or therapy-related, leukemias show signs
of MMR deficiency.17,18 Collectively, these results show the
broad involvement of MMR in mediating drug response, the
effects of MMR deficiency on this response, and the need to
develop therapeutic agents that specifically target MMR-de-
ficient cells.
Our laboratory has previously developed bulky rhodium
complexes that target DNA mismatches in Vitro.19-23 These
octahedral complexes contain an expansive tetracyclic aromatic
ligand that can be accommodated preferentially by DNA at a
thermodynamically destabilized mismatch site. The first-genera-
tion compound, Rh(bpy)2chrysi3+ (chrysi ) 5,6-chrysenequinone
diimine), binds 80% of DNA mismatches with typical binding
constants of 106 M-1 and remarkable specificity for mismatched
DNA; in a 2.6 kb DNA fragment DNA photocleavage reveals
specific targeting of the mismatch.19,20,23 Subsequent work led
to the incorporation of nitrogen atoms into the intercalating
ligand and a 50-fold increase in binding affinity for the second-
generation compound, Rh(bpy)2phzi3+ (phzi ) benzo[a]-phena-
zine-5,6-quinonediimine).21 A high-resolution crystal structure
of Rh(bpy)2chrysi3+ bound to single AC mismatches within a
DNA oligonucleotide duplex reveals a distinctive binding mode
at the mismatched site.24 We had previously determined that
tris(chelate) complexes of Rh with a planar aromatic ligand bind
to well-matched DNA by partial intercalation of the planar
ligand from the major groove side into the base pair stack.25
However, binding to the mismatched site involves instead
insertion of the expansive ligand into the DNA duplex from
the minor groove side at the mismatched site with ejection of
the mismatched bases out of the DNA stack; the inserted ligand
stacks fully with adjacent base pairs. NMR studies of
Rh(bpy)2chrysi3+ bound to an oligonucleotide containing a CC
mismatch confirm this metalloinsertion mode for the complex
at mismatched sites in solution.26
The in ViVo effects of Rh(bpy)2chrysi3+ and Rh(bpy)2phzi3+
have been characterized in the isogenic cell lines HCT116N
and HCT116O.27 The HCT116 cell line is a colorectal carcinoma
line deficient in the hMLH1 gene. Two derivative cell lines,
HCT116N and HCT116O, have been made through transfection
of human chromosome 3 (ch3) and human chromosome 2 (ch2),
respectively. The presence of a functional copy of ch3 restores
MMR proficiency in the HCT116N line, while the HCT116O
line transfected with ch2 remains MMR deficient.28 The
mismatch recognition compounds developed within our labora-
tory were shown to selectively inhibit the proliferation of the
repair-deficient HCT116O line.27
Recent work within our laboratory on luminescent ruthenium
complexes has also shown that these tris(chelate) complexes
are taken up inside cells through passive diffusion facilitated
by the membrane potential.29 Variations in ancillary ligands have
dramatic effects on cellular uptake, with increased lipophilicity
facilitating uptake. Uptake can also be increased through
functionalization with a nuclear localizing peptide.30
Here we examine the effects of ancillary ligand variation in
the Rh(L)2chrysi3+ family on the ability of these complexes to
target DNA mismatches in Vitro and in ViVo. Importantly, we
establish that the differential inhibition of cellular proliferation
in MMR-deficient cells is correlated with mismatch binding
affinity.
Experimental Procedures
Materials. RhCl3 was purchased from Pressure Chemical, Inc.
(Pittsburgh, PA). [Rh(NH3)5Cl]Cl2 was obtained from Strem
Chemical, Inc. (Newburyport, MA). 2,2′-Dipyridylamine (HDPA),
4,7-diphenyl-1,10-phenanthroline (DIP), and Sephadex ion-ex-
change resin were obtained from Sigma-Aldrich (St. Louis, MO).
Sep-Pak C18 solid-phase extraction cartridges were purchased from
Waters Chemical Co. (Milford, MA). Phosphoramidites were
purchased from Glen Research (Sterling, VA). Media and supple-
ments were purchased from Invitrogen (Carlsbad, CA). BrdU,
antibodies, buffers, and peroxidase substrate were purchased in kit
format from Roche Molecular Biochemicals (Mannheim, Germany).
All commercial materials were used as received.
Oligonucleotide Synthesis. Oligonucleotides were synthesized
on an Applied Biosystems 3400 DNA synthesizer using standard
phosphoramidite chemistry. DNA was synthesized with a 5′-
dimethoxytrityl (DMT) protecting group. The oligonucleotides were
cleaved from the beads by reaction with concentrated ammonium
hydroxide at 60 °C overnight. The resulting free oligonucleotides
were purified by HPLC using a C18 reverse-phase column (Varian,
Inc.) on a Hewlett-Packard 1100 HPLC. The DMT group was
removed by reaction with 80% acetic acid for 15 min at room
temperature. The DMT-free oligonucleotides were precipitated with
absolute ethanol and purified again by HPLC. Positive identification
of the oligonucleotides and their purity were confirmed by MALDI-
TOF mass spectrometry. Quantification was performed on a
Beckman DU 7400 spectrophotometer using the extinction coef-
ficients at 260 nm (ε260) estimated for single-stranded DNA.
Synthesis and Characterization of Metal Complexes. Chry-
sene-5,6-dione, [Rh(bpy)2chrysi]Cl3, and [Rh(phen)2chrysi]Cl3 were
prepared according to previously reported procedures.19,20,31
[Rh(NH3)4chrysi]OTf3. [Rh(NH3)6]OTf3 was prepared as de-
scribed by Sargeson.32,33 [Rh(NH3)6]OTf3 was reacted with a
limiting amount of chrysene quinone in a 3:1 acetonitrile:water
mixture with excess sodium hydroxide as a catalyst to form
[Rh(NH3)4chrysi]OTf3. Acetonitrile was removed in Vacuo, followed
by filtration to remove unreacted chrysenequinone. The product was
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separated from unreacted [Rh(NH3)6]OTf3 by solid-phase extraction
on a C18 cartridge and eluted with 1:1:0.001 acetonitrile:water:TFA.
1H NMR (DMSO-d6, 50 °C, 300 MHz): δ 13.30 (s), 12.32 (s),
8.876 (t, 1H, 7.7 Hz), 8.787 (d, 1H, 7.9 Hz), 8.57-8.51 (m, 2H),
8.358 (dd, 1H, 8.9 Hz, 4.6 Hz), 8.145 (d, 1H, 7.7 Hz), 7.85-7.70
(m, 4H), 4.73-4.54 (broad m, 6H), 3.862 (s, 3H) ppm. UV/vis
(H2O, pH 5): 263 nm (60 900 M-1 cm-1), 283 nm (38 100 M-1
cm-1), 326 nm (12 600 M-1 cm-1), 413 nm (12 000 M-1 cm-1).
MALDI-MS (cation): 425 m/z (M - 2H+) obsd, 427 m/z calcd.
rac-[Rh(HDPA)2(chrysi)]OTf3. [Rh(NH3)4(chrysi)]OTf3 (15 mg,
0.02 mmol) was reacted with HDPA (20 mg, 0.12 mmol, excess)
in 20 mL of ethanol and 20 mL of water. The dark red solution
was heated under reflux for 16 h. The reaction mixture turned
reddish brown upon heating. Ethanol was removed under vacuum,
and the resulting solution was filtered to remove any residue. The
filtrate was concentrated on a Sep-Pak C18 cartridge, eluting with
1:1:0.01 acetonitrile:water:TFA, lyophilized, and purified on an
alumina column, eluting with 2% methanol in dichloromethane.
The fractions were collected and dried under vacuum to give an
orange-brown solid (8 mg, 39%). 1H NMR (DMSO-d6, 300 MHz):
δ 12.84 (s, 1H), 12.34 (s, 1H), 11.78 (s, 1H), 10.32 (d, 1H, 8.7
Hz), 8.63 (d, 1H, 6.9 Hz), 8.40 (d, 1H, 8.4 Hz), 8.31 (d, 1H, 9.3
Hz), 8.14 (m, 2H), 8.07 (d, 1H, 8.7 Hz), 8.04 (d, 1H, 5.4 Hz), 7.94
(m, 4H), 7.77 (m, 5H), 7.58 (m, 2H), 7.48 (d, 1H, 8.1 Hz), 7.41 (d,
1H, 8.4 Hz), 7.32 (s, 1H), 7.14 (m, 2H), 7.04 (t, 1H, 6.8 Hz), 6.98
(t, 1H, 6.9 Hz), 6.81 (t, 1H, 6.5 Hz) ppm. UV/vis (H2O, pH 5):
287 nm (42 200 M-1 cm-1), 321 nm (23 000 M-1 cm-1), 442 nm
(8800 M-1 cm-1). ESI-MS (cation): 699.2 m/z (M - 2H+), 350.1
m/z (M - H2+) obsd, 699.2 m/z (M - 2H+) calcd.
rac-[Rh(DIP)2(NH3)2]OTf3. RhCl3 and 2 equiv of DIP were
combined in 1:1 ethanol:water and refluxed overnight. The solvent
was removed in Vacuo, and the product was recrystallized by
dissolving in acetonitrile at 60 °C and cooling to -20 °C. The
precipitate was collected by filtration, washed in diethyl ether, and
dissolved in neat triflic acid. The solution was again cooled and
added dropwise to NH4OH at -20 °C. The pale white precipitate
was collected by filtration and washed with a small amount of water
to give [Rh(DIP)2(NH3)2]OTf3.
rac-[Rh(DIP)2chrysi]Cl3. rac-[Rh(DIP)2(NH3)2]OTf3 was com-
bined with a 10% excess of 5,6-chrysenequinone and a catalytic
amount of NaOH in acetonitrile and stirred at room temperature
overnight. The condensation was terminated by addition of a
stoichiometric amount of HCl. The solvent was removed in Vacuo,
and the product was purified by alumina column chromatography.
Unbound chrysi ligand eluted first with ethyl acetate, and the
purified product then eluted with acetonitrile. Finally, the compound
was dissolved in 3:2 MeCN:H2O, and the triflate counterion was
exchanged for chloride ion with Sephadex QAE-125 ion-exchange
resin. UV/vis (H2O, pH 5): 290 nm (104 000 M-1 cm-1), 335 nm
(43 900 M-1 cm-1), 373 nm (22 300 M-1 cm-1). ESI-MS (cation):
1020.9 m/z (M - 2H+), 511.0 m/z (M - H2+) obsd, 1023 m/z (M
- H2+) calcd.
Photocleavage Titrations. The oligonucleotide was 32P-labeled
at the 5′-end by incubating DNA with 32P-ATP and polynucleotide
kinase (PNK) at 37 °C for 2 h, followed by purification using gel
electrophoresis. A small amount of the labeled DNA (less than 1%
of the total amount of DNA) was added to 2 µM DNA in 100 mM
NaCl, 20 mM NaPi, pH 7.1 buffer. The DNA hairpin was annealed
by heating at 90 °C for 10 min and cooling slowly to room
temperature over a period of 2 h. Racemic rhodium complex
solutions ranging from nanomolar to micromolar concentration were
made in Milli-Q water. Annealed 2 µM DNA (10 µL) and 10 µL
of Rh solution at each concentration were mixed in a microcen-
trifuge tube and incubated at 37 °C for 10 min. A light control
(LC), in which the DNA was mixed with 10 µL of water and
irradiated, and a dark control (DC), in which the DNA was mixed
with the highest concentration of rhodium complex without
irradiation, were also prepared. The samples were left in the heat
block and irradiated on an Oriel (Darmstadt, Germany) 1000-W
Hg/Xe solar simulator (340-440 nm) for 5 min. The irradiated
samples were dried and electrophoresed in a 20% denaturing
polyacrylamide gel. The gel was then exposed to a phosphor screen,
and the relative amounts of DNA in each band were quantitated
by phosphorimagery (ImageQuant).
Binding Constant Determination. The fraction of DNA cleaved
in each lane on the gel was normalized and plotted against the log
of the concentration of rhodium complex. At least three photo-
cleavage titrations were carried out for each racemic metal complex.
The pooled data were fit to a sigmoidal curve using OriginPro 6.1.
The resulting midpoint value (i.e., the log of [rhodium complex]
at the inflection point of the curve) was converted to units of
concentration ([Rh50%]). The dissociation constant was calculated
according to KD ) [Rh50%] - 0.5[DNA], and the binding constant
was defined as KB ) 1/KD. The errors were derived from the errors
associated with the midpoint values. For complexes that did not
photocleave DNA, a binding competition titration was carried out
with a constant amount (1 µM) of rac-Rh(bpy)2(chrysi)3+ added
to each sample. The binding and dissociation constants of the non-
photocleaving complex were calculated by solving simultaneous
equlibiria involving DNA, Rh(bpy)2(chrysi)3+, and the complex in
question in Mathematica 6.0.
Cell Culture. HCT116N and HCT116O cells were grown in
RPMI medium 1640 supplemented with 10% FBS, 2 mM L-
glutamine, 0.1 mM nonessential amino acids, 1 mM sodium
pyruvate, 100 units/mL penicillin, 100 µg/mL streptomycin, and
400 µg/mL Geneticin (G418). Cells were grown in tissue culture
flasks and dishes (Corning Costar, Acton, MA) at 37 °C under 5%
CO2 atmosphere.
Cellular Proliferation ELISA. HCT116N and HCT116O cells
were plated in 96-well plates at 2000 cells/well and allowed 24 h
to adhere. The cells were then incubated with rhodium complexes
for the durations specified. For incubation less than 72 h, the Rh-
containing medium was replaced with fresh medium, and the cells
were grown for the remainder of the 72 h period. Cells were labeled
with BrdU 24 h before analysis. The BrdU incorporation was
quantified by antibody assay according to established procedures.34,35
Cellular proliferation was expressed as the ratio of the amount of
BrdU incorporated by the treated cells to that of the untreated cells.
Results
Binding Affinities for Metal Complexes at Single Base
Mismatches. The binding constants of the family of
Rh(L)2chrysi3+ complexes at a CC and AC mismatch in a 29-
mer DNA hairpin with the sequence 5′-GGCAGGXATG-
GCTTTTTGCCATCCCTGCC-3′ (X ) C or A, underline
denotes the mismatch) were measured. The hairpin sequence
allows cleavage site determination on either strand around the
DNA mismatch site. By irradiating samples of DNA titrated
with varying concentrations of a rhodium complex, a photo-
cleavage titration curve is obtained from which the binding
constant of the rhodium complex is determined. A typical
autoradiogram, taken after electrophoresis through a denaturing
gel, of samples in a photocleavage titration with rac-Rh(bpy)2-
chrysi3+ at a CC mismatch is shown in Figure 2. The position
of the photocleavage bands indicates that Rh(bpy)2chrysi3+
cleaves one base neighboring the mismatch site near the 3′-
end. For this DNA sequence, we observed cleavage on only
one strand as reported earlier.23 This cleavage pattern is found
for both rac-Rh(phen)2chrysi3+ and rac-Rh(DIP)2chrysi3+ and
holds for the AC mismatch for rac-Rh(bpy)2chrysi3+ and rac-
Rh(phen)2chrysi3+. No other photocleavage bands are observed,
(34) Reitmar, A. H.; Risley, R.; Bristow, R. G.; Wilson, T.; Ganesh, A.;
Jang, A.; Peacock, J.; Benchimol, S.; Hill, R. P.; Mak, T. W.; Fishel,
R.; Meuth, M. Cancer Res. 1997, 57, 3765–3771.
(35) Gratzner, H. G. Science 1982, 218, 474–475.
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demonstrating the high specificity of Rh(L)2chrysi3+ complexes
binding to the mismatch. The photocleavage titration curve is
generated from the autoradiogram by quantifying the amount
of photocleavage relative to the total amount of DNA at each
Rh concentration. Pooled data from at least three repeats were
fitted to a sigmoidal curve (Figure 2) for determination of the
midpoint ([Rh50%]) and the dissociation constant (KD). The KD
value for rac-Rh(bpy)2chrysi3+ at a CC mismatch is found to
be 30 nM. For rac-Rh(phen)2chrysi3+ and rac-Rh(DIP)2chrysi3+
at a CC mismatch, KD values of 320 nM and 11 µM are found,
respectively (corresponding KB values are shown in Table 1).
For the AC mismatch with both rac-Rh(bpy)2chrysi3+ and rac-
Rh(phen)2chrysi3+, KD values are somewhat higher, as we expect
given the greater thermodynamic stability of an AC mismatch
versus a CC mismatch. rac-Rh(DIP)2chrysi3+ does not yield any
photocleavage up to 100 µM; thus, its KD value is estimated to
be greater than that.
As with phenanthrenequinone diimine complexes of rhodium
containing saturated amine ligands, Rh(NH3)4 chrysi3+ and rac-
Rh(HDPA)2chrysi3+ promote relatively little DNA cleavage
upon irradiation.36 As a result, their binding affinities were
determined through binding competition titrations with 1 µM
rac-Rh(bpy)2chrysi3+. On the basis of the binding constant of
Rh(bpy)2chrysi3+, the binding constant of Rh(NH3)4chrysi3+ is
calculated by solving simultaneous equilibria at the inflection
point of the photocleavage titration curve. Through this com-
petitive titration, the binding constant of Rh(NH3)4chrysi3+ at a
CC mismatch is found to be 1.0 × 108 M-1. At an AC mismatch,
KB of Rh(NH3)4chrysi3+ is 3.4 × 106 M-1. From similar binding
competition titrations, the binding constant of rac-Rh(HD-
PA)2chrysi3+ is found to be 2.0 × 107 M-1 at a CC mismatch
and 2.6 × 106 M-1 at an AC mismatch. It is apparent that the
binding affinity correlates inversely with complex size; the
smallest complex, Rh(NH3)4chrysi3+, shows the highest affinities
for mismatched sites. The binding constants for the entire series
of Rh(L)2chrysi3+ complexes are summarized in Table 1.
Inhibition of Cellular Proliferation by Enzyme-Linked
Immunosorbent Assay (ELISA). An ELISA for DNA synthesis
was used to quantify the effects of the metalloinsertors on the
proliferation of HCT116N cells (MMR-proficient) and HCT116O
cells (MMR-deficient).27 Both cell lines were incubated with
0-25 µM of each member of the Rh(L)2chrysi3+ family except
Rh(DIP)2chrysi3+, which was administered at 0-5 µM concen-
trations due to its greater uptake characteristics. Incubations were
performed for 12, 24, 48, or 72 h. After the 12, 24, and 48 h
incubations, the medium containing Rh was replaced with fresh
medium, and the cells were grown for the remainder of the 72 h
period. The extent of cellular proliferation is expressed as the
ratio of BrdU incorporated by the rhodium-treated cells as
(36) Krotz, A. H.; Kuo, L. Y.; Shields, T. P.; Barton, J. K. J. Am. Chem.
Soc. 1993, 115, 3877–3882.
Figure 1. Rh(L)2chrysi3+ family of metalloinsertors.
Figure 2. Binding affinities determined through DNA photocleavage. The
DNA hairpin sequence is 5′-GGCAGGXATGGCTTTTTGCCATCCCT-
GCC-3′ (X ) C or A, underline denotes the mismatch). Samples were
irradiated and electrophoresed through a 20% denaturing PAGE gel. A light
control (LC, without rhodium) and dark control (DC, without irradiation)
were included. A representative autoradiogram of a photocleavage titration
with rac-Rh(bpy)2chrysi3+ (A, arrows indicate positions of mismatched
bases) and a representative sigmoidal curve fit of pooled data from
photocleavage titrations for binding constant determination (B) are shown.
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compared to untreated controls. Figure 3 shows representative
data for Rh(NH3)4chrysi3+ at various incubation times. No
significant preferential inhibition of the HCT116O cell line is
seen at incubation times less than 24 h, consistent with previous
results for Rh(bpy)2chrysi3+, with the exception of Rh(DIP)2-
chrysi3+, which displays a small differential effect at 12 h.27
With longer incubation times, however, Rh(NH3)4chrysi3+
displays a strong differential effect with preferential inhibition
of the MMR-deficient HCT116O cell line over the MMR-
proficient HCT116N cell line. In particular, 48 h treatment with
10 µM Rh(NH3)4chrysi3+ inhibits the proliferation of the
HCT116O line by 82 ( 2% while exerting little to no effect on
the HCT116N line (7 ( 6% inhibition).
Figure 4 shows the ELISA results for members of the
metalloinsertor family as a function of incubation time. We have
shown previously that the Λ-enantiomer of Rh(bpy)2chrysi3+
is biologically inactive27 and that structurally binding to a
mismatch site is enantiospecific for the ∆-isomer.24 For this
reason, treatment with the 10 µM achiral tetraammine complex
was compared to treatment with 20 µM racemic mixtures of
the Rh(L)2chrysi3+ complexes (L ) HDPA, bpy, or phen). The
differential effect of rhodium treatment between the cells lines
was quantified by subtracting the normalized percentages of
cellular proliferation for each cell line. Notably, the optimal
incubation time for each compound is inversely related to the
hydrophobicity of the ancillary ligands, with rac-Rh(phen)2-
chrysi3+ exhibiting an optimal incubation time of 24 h. This
trend also continues with rac-Rh(DIP)2chrysi3+, which exhibits
differential effects in as little as 12 h at concentrations as low
as 2 µM (Figure 5). Based on the early effect at 12 h, the HDPA
complex may have different uptake characteristics; the analogous
Ru complex has not yet been examined using flow cytometry.
With the exception of the HDPA complex, this variation in
activity with incubation time for the family of complexes
parallels closely results seen earlier for uptake in HeLa cells
by Ru(bpy)2dppz2+, Ru(phen)2dppz2+, and Ru(DIP)2dppz2+,
where the most rapid uptake is apparent with the lipophilic DIP
complex.29
Figure 6 summarizes the differential effects on cell prolifera-
tion and the incubation time for the family of complexes. Clear
correlations with the binding constants for these complexes are
Table 1. Binding Affinitiesa of Rh(L)2chrysi3+ Complexesb for CC
and AC Mismatches
a Uncertainties are estimated to be 10%. Binding constants are
determined from photocleavage or binding competition titrations using a
DNA hairpin with the sequence 5′-GGCAGGXATGGCTTTTTGC-
CATCCCTGCC-3′ (X ) C or A, underline denotes the mismatch).
Samples were irradiated with a solar simulator (340-440 nm) at 37 °C
in 50 mM NaCl, 10 mM NaPi, pH 7.1, as described in the Experimental
Procedures. b For the polypyridyl complexes, values are given for
racemic mixtures.
Figure 3. Inhibitory effects of Rh(NH3)4chrysi3+ as a function of incubation
time on cellular proliferation. Shown are plots of BrdU incorporation (a
measure of DNA synthesis and therefore cellular proliferation) normalized
to the BrdU incorporation of untreated cells as a function of rhodium
concentration. Standard error bars for five trials are shown. MMR-proficient
HCT116N cells (green) and MMR-deficient HCT116O cells (red) were
plated and allowed 24 h to adhere before incubation with 0-25 µM
Rh(NH3)4chrysi3+ for 12, 24, 48, or 72 h. At the end of the 12, 24, and
48 h incubations, the medium containing Rh was replaced with fresh medium
for the remainder of the 72 h, followed by ELISA analysis. BrdU was added
to the medium 24 h prior to analysis.
J. AM. CHEM. SOC. 9 VOL. 131, NO. 6, 2009 2363
Rhodium Metalloinsertors Targeting DNA Mismatches A R T I C L E S
evident (Table 1). Significantly, the differential effect in
inhibiting cell proliferation in MMR-deficient cells is directly
correlated to the binding affinity of the compound for DNA
mismatches. Rh(NH3)4chrysi3+ (KB ) 1 × 108 M-1 at a CC
mismatch), for example, shows the largest differential effect in
inhibiting proliferation of MMR-deficient versus -proficient
HCT116 cells after 72 h (79 ( 5%), while Rh(phen)2chrysi3+
(KB ) 3.2 × 106 M-1 at a CC mismatch) shows a small
differential effect (17 ( 7%). The DIP complex is rapidly taken
up by the cells but also shows only a small differential inhibitory
effect correlating with its poor specific binding at the mismatch
site.
Discussion
A clear trend emerges when comparing the binding constants
of the series of rhodium complexes to mismatched sites: the
DNA mismatch binding affinity increases as the size of the
ancillary ligand decreases. This trend is consistent with what
we have learned from the structural studies, specifically that
mismatch binding by insertion via the minor groove is subject
to stringent space constraints. With major groove intercalation,
the base rise is increased and the major groove offers space to
accommodate the ancillary ligands. In contrast, with insertion,
there is no increase in base pair rise; the mismatched bases are
instead ejected and replaced by the deeply inserted chrysi ligand.
Moreover, the minor groove, small even for hydrophobic groove
binding molecules, offers little space for the ancillary ligands.
While little enantioselectivity is apparent for intercalation of
bpy complexes into B-form DNA, ∆-Rh(bpy)2chrysi3+ binds
enantiospecifically to single base mismatches.24,37 Thus steric
interactions of the ancillary ligands are seen as an extremely
important factor governing the binding affinity of a metal
complex at the mismatch site.
We have previously demonstrated that mismatch binding
affinity is correlated with thermodynamic destabilization over
all mismatch identities and sequence contexts.20,23 Here, we see
for all the complexes that binding to the CC mismatch is tighter
than binding to the AC mismatch. This is consistent with our
previous observations, since AC is the thermodynamically more
stable mismatch and, in this case, is estimated to stabilize the
hairpin duplex by ∼0.5 kcal/mol relative to one containing a
(37) Barton, J. K. Science. 1986, 233, 727–734.
(38) SantaLucia, J., Jr.; Hicks, D. Annu. ReV. Biophys. Biomol. Struct. 2004,
33, 415–440.
(39) Rajendiran, V.; Murali, M.; Suresh, E.; Palaniandavar, M.; Periasamy,
V. S.; Akbarsha, M. A. Dalton Trans. 2008, 2157–2170.
(40) Napolitano, S. M.; Aprille, J. R. AdV. Drug DeliVery ReV. 2001, 49,
63–70.
Figure 4. Inhibitory effects of rhodium metalloinsertors as a function of
incubation time. Shown are plots of BrdU incorporation normalized to the
BrdU incorporation of untreated cells as a function of rhodium concentration.
The inhibition differential is the difference of the normalized percentages
of cellular proliferation for each cell line, with standard error bars (SN-O )
(sN2 + sO2)). ELISA analyses were performed as in Figure 3. Cells were
incubated with no rhodium, 2 µM rac-Rh(DIP)2chrysi3+, 10 µM
Rh(NH3)4chrysi3+, or 20 µM rac-Rh(L)2chrysi3+ (L ) HDPA, bpy, or phen).
Figure 5. Inhibitory effects of rac-Rh(DIP)2chrysi3+. Shown are plots of
BrdU incorporation normalized to the BrdU incorporation of untreated cells
as a function of rhodium concentration. Standard error bars for five trials
are shown. MMR-proficient HCT116N cells (green) and MMR-deficient
HCT116O cells (red) were plated and allowed 24 h to adhere before
incubation with 0s5 µM rac-Rh(DIP)2chrysi3+ for 12 h. At the end of the
incubation, the medium containing Rh was replaced with fresh medium,
and cells were grown for an additional 60 h before ELISA analysis. BrdU
was added to the medium 24 h prior to analysis.
Figure 6. Inhibitory effects of rhodium metalloinsertors as a function of
metal complex identity. Shown are bar graphs of BrdU incorporation
normalized to the BrdU incorporation of untreated cells as a function of
rhodium concentration. The inhibition differential is the difference of the
normalized percentages of cellular proliferation for the two cell lines,
HCT116O versus HCT116N. ELISA analyses were performed as in Figure
3. Cells were incubated with no rhodium, 2 µM rac-Rh(DIP)2chrysi3+, 10
µM Rh(NH3)4chrysi3+, or 20 µM rac-Rh(L)2chrysi3+ (L ) HDPA, bpy, or
phen). A correlation between mismatch binding affinity and differential
inhibition of MMR-deficient cells is evident.
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CC mismatch.38 We assume, then, that the general trend holds
for all members of this metalloinsertor family. This stabilization
is translated into a higher dissociation constant (smaller binding
affinity) for the entire series of rhodium complexes. This
decrease in binding affinity depends upon the greater energy
required to eject the mismatched bases from the base pair stack,
as evident crystallographically and by NMR.24,26 Nonetheless,
for the family of chrysi complexes, the inverse relationship
between the size of the ancillary ligand and the binding affinity
still holds, with the smallest complex Rh(NH3)4chrysi3+ showing
the highest affinity and that of the largest complex, Rh(DIP)2-
chrysi3+, more than 2 orders of magnitude lower.
Figure 7 compares the crystal structure of ∆-Rh(bpy)2chrysi3+
bound to the mismatch site24 with models of ∆-Rh(DIP)2chrysi3+
and Rh(NH3)4chrysi3+ similarly bound via the minor groove
through metalloinsertion. Preserving the DNA conformation
from the crystal structure, we see that ∆-Rh(DIP)2chrysi3+ runs
into substantial steric hindrance, as its axial phenyl rings extend
up and down into the groove, directly clashing with the bases.
However, its equatorial phenyl rings do not pose any steric
problems, as they point away from the DNA. These observations
are supported by the small binding constant measured for
Rh(DIP)2chrysi3+. Rh(phen)2chrysi3+, intermediate in size,
shows binding affinities for the mismatches that are an order
of magnitude lower than those of the bpy derivative but more
than an order of magnitude higher than those of the DIP
complex. Rh(HDPA)2chrysi3+ is slightly larger in size than the
bpy derivative, but the HDPA ligands are more flexible, and
there is an opportunity for hydrogen bonding; as a result,
Rh(bpy)2chrysi3+ and Rh(HDPA)2chrysi3+ have comparable
affinities for the mismatch. Analogously, the large binding
constant of Rh(NH3)4chrysi3+ can be mostly attributed to its
small size. Here it is reasonable to suggest that the axial
ammines may also hydrogen bond with the neighboring base
pairs to form additional stabilizing interactions. Nonetheless,
as evident in Figure 7, the small cone size of the tetraammine
structure clearly facilitates deep insertion within the minor
groove site. In fact, the clear inverse correlation of binding
affinity with ancillary ligand size, and the finding that
Rh(DIP)2chrysi3+, despite its cumbersome size, is able to bind
at all to a mismatch site with some specificity, corroborate our
understanding of the driving force and the dynamics of mismatch
recognition: the π-stacking between the inserted chrysi ligand
and the adjacent bases provides the major stabilizing force for
binding, and both the metal complex and DNA distort their
conformations to accommodate each other in the bound state.
Importantly, the DNA mismatch binding affinities of the
Rh(L)2chrysi3+ family correlate well with the differential
biological effects seen between the repair-proficient HCT116N
and repair-deficient HCT116O cell lines. This correlation
supports the hypothesis that DNA mismatches are the target of
rhodium metalloinsertors in ViVo. Because of this correlation,
we may attribute the preferential inhibitory effect on MMR-
deficient cells to binding of the complexes to DNA mismatches.
Since the MMR-deficient cells contain more mismatches, the
tighter binding complexes would be expected to display a greater
inhibitory effect. It should be noted that finding any inhibitory
effect with these complexes was at first surprising, since they
bind DNA noncovalently and might be expected to be
readily displaced. Although the mechanism of inhibition is not
yet fully understood, it is likely that protein recognition of the
metal-mismatch complex, perhaps by RNA polymerase or
Figure 7. Crystal and model structures of rhodium metalloinsertors bound
to the mismatch site. Rhodium insertors (red) are shown bound to the DNA
(gray) from the minor groove at the mismatch site with the bases (adenine
in blue, cytosine in yellow) ejected and the chrysi ligand stacked fully with
the adjacent base pairs. The crystal structure of ∆-Rh(bpy)2chrysi3+ bound
to the CA mismatch is shown in panel (A), along with structural models of
∆-Rh(DIP)2chrysi3+ (B) and ∆-Rh(NH3)4chrysi3+ (C) binding based on the
crystal structure. Superposition of the DIP complex upon the rhodium center
of the bpy complex leads to steric clashes with the sugar-phosphate
backbone (possible atoms involved in green), whereas the tetraammine
complex is easily accommodated.
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topoisomerase, may generate a covalent protein-DNA lesion
and contribute to the cellular response.
The differential inhibitory effect seen with Rh(HD-
PA)2chrysi3+ cannot be understood simply on the basis of
binding affinities. Despite having essentially the same mismatch
binding affinity as Rh(bpy)2chrysi3+, the HDPA complex
preferentially inhibits the MMR-deficient cell line almost as well
as Rh(NH3)4chrysi3+ with long incubation times; with short
times of incubation, the differential inhibitory effect by
Rh(HDPA)2chrysi3+ is greatest. Both the HDPA ligand and the
amine group have the potential to form hydrogen bonds. This
hydrogen bonding capability and flexibility of the ligands might
serve to make them more effective inhibitors of any protein-DNA
interactions. Indeed, ruthenium complexes bearing HDPA
ligands have been shown to exhibit DNA binding and cytotox-
icity.39
Certainly, as with any pharmaceutical design, cellular uptake
must also be considered. In the case of the HDPA complex,
based upon the variations in inhibitory effect with incubation
time, the amine ligands may facilitate nuclear uptake. Dppz
analogues with the HDPA ligands have not yet been examined
with respect to their uptake characteristics. For the bpy
complexes, the 48 h incubation time required for Rh(bpy)2-
chrysi3+ to exert its anti-proliferative effect matches the 48 h
requirement observed for Ru(bpy)2dppz2+ uptake in HeLa
cells.27,29 The more lipophilic Rh(DIP)2chrysi3+ here is found
to exert anti-proliferative effects at much shorter incubation
times and lower concentrations, which also matches the ac-
celerated uptake observed for Ru(DIP)2dppz2+. Cellular uptake
is surely a rate-limiting factor in biological activity of the
rhodium metalloinsertors, yet cellular uptake is not the only
challenge: proper subcellular localization must also be achieved
in order for any drug to act upon its target. It has been well
established that lipophilic cations preferentially target the
mitochondria, whereas hydrophilic cations do not.40,41 It may
be that Rh(HDPA)2chrysi3+ and Rh(NH3)4chrysi3+ lack the
lipophilicity required for mitochondrial accumulation, allowing
a greater proportion of these compounds to reach the nucleus
once inside the cell. This difference in intracellular partitioning
could then account for the differential effects of Rh(HD-
PA)2chrysi3+.
In the development of octahedral rhodium complexes as anti-
cancer agents, the choice of ancillary ligand can be seen as a
design tradeoff, with the binding affinity for a DNA mismatch
greatly outweighing uptake properties as the critical factor in
the successful targeting of repair- deficient cells. Beyond their
effects on DNA binding and overall cellular uptake, it is highly
likely that the ancillary ligands affect the cellular response in
other ways, including the potential for hydrogen bonding and
differences in uptake and intracellular distribution. Here we are
confronted with a tradeoff that may seem inevitable: more
hydrophobic ligands facilitate cellular uptake but impede
mismatch binding. Perhaps this tradeoff can be avoided by
making conjugates arranged with functional moieties tethered
with consideration of the structure of the DNA-bound complex
associated snugly in the minor groove. Most importantly, these
data support the contention that the cell-specific inhibitory effect
we observe depends upon binding to the DNA mismatch inside
the cell. This cell-specific strategy thus represents a promising
direction in the development of small metal complexes that react
preferentially in MMR-deficient cells, those susceptible to
cancerous transformation.
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